Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015;11(3):553-63.
doi: 10.1080/21645515.2015.1011562.

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Barbara Camilloni  1 , Michela Basileo, Stefano Valente, Emilia Nunzi, Anna Maria Iorio
Affiliations
Comparative Study

Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review

Barbara Camilloni et al. Hum Vaccin Immunother. 2015.

Abstract

Because of the age-related immune system decline, 2 potentiated influenza vaccines were specifically licensed for the elderly: Fluad(®), an MF59-adjuvanted vaccine administered intramuscularly (IM-MF59), and Intanza 15 mcg(®), a non adjuvanted vaccine administered intradermally (ID). The objective of this paper was to conduct a systematic review of studies that evaluated antibody responses in the elderly following immunization with IM-MF59 or ID vaccines. The two potentiated vaccines induced immune responses satisfying, in most instances, the European Medicine Agency immunogenicity criteria, both against vaccine antigens and heterovariant drifted strains. Considering pooled data reported in the articles analyzed and papers directly comparing the 2 vaccines, the antibody responses elicited by IM-MF59 and ID were found to be generally comparable. The use of IM-MF59 and ID vaccines can be proposed as an appropriate strategy for elderly seasonal influenza vaccination although further studies are required for a more complete characterization of the 2 vaccines.

Keywords: APC, Antigen-presenting cells; DC, Dendritic cell; EMA, European Medicine Agency; GMTR, Geometric Mean Titer Ratio; HA, Haemagglutinin; HI, Haemagglutination inhibiting; ID, Intradermal; IM-MF59, Intramuscular MF59; NT, Neutralization; adjuvanted vaccine; elderly; immunogenicity; influenza vaccine; intradermal vaccine; potentiated vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A-C). Comparison of pooled literature data of EMA immunogenicity criteria (seroprotection, GMTR and seroconversion) against the 3 influenza antigens after immunization of people aged ≥60 y with IM-MF59 or ID influenza vaccines. The abscissa in each figure reports the antigen A/H3, A/H1 and B and each symbol represents the estimated mean value with its 95% confidence interval of the parameter indicated on the ordinate axis for the 2 vaccines (circled markers (•) represent IM-MF59; triangular markers (▾) represent ID). The horizontal dashed line indicates the EMA threshold level for each parameter.
See this image and copyright information in PMC

References

    1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333 - DOI - PubMed
    1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/jama.289.2.179 - DOI - PubMed
    1. Gaillat J, Dennetiere G, Raffin-Bru E, Valette M, Blanc MC. Summer influenza outbreak in a home for the elderly: application of preventive measures. J Hosp Infect 2008; 70:272-7; PMID:18799243; http://dx.doi.org/10.1016/j.jhin.2008.07.009 - DOI - PubMed
    1. Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40; PMID:11599686; http://dx.doi.org/10.1023/A:1017919305501 - DOI - PubMed
    1. McElhaney JE, Hooton JW, Hooton N, Bleackley RC. Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine 2005; 23:3294-300; PMID:15837235; http://dx.doi.org/10.1016/j.vaccine.2005.01.080 - DOI - PubMed

MeSH terms